Information
-
Trademark
-
97187198
-
International Classifications
-
Filing Date
December 23, 2021
3 years ago
-
Transaction Date
September 30, 2024
3 months ago
-
Status Date
September 30, 2024
3 months ago
-
Published for Opposition Date
January 02, 2024
a year ago
-
Location Date
February 27, 2024
10 months ago
-
First Use Anywhere Date
December 07, 2017
7 years ago
-
First Use In Commerce Date
May 15, 2018
6 years ago
-
Status Code
606
-
Current Location
INTENT TO USE SECTION
Employee Name
MACFARLANE, JAMES
-
Attorney Docket Number
S21802000000
Attorney Name
Christina M. Licursi
Law Office Assigned Location Code
L40
-
Owners
Mark Drawing Code
4
Mark Identification
SWANBIO THERAPEUTICS
Case File Statements
- GS0051: Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders; none of the foregoing constituting reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays
- PM0001: SWAN BIO THERAPEUTICS
- GS0421: Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development; none of the foregoing relating to reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays
Case File Event Statements
-
12/30/2021 - 3 years ago
1 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
9/27/2022 - 2 years ago
2 - ASSIGNED TO EXAMINER
Type: DOCK
-
10/11/2022 - 2 years ago
3 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
10/11/2022 - 2 years ago
4 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
10/11/2022 - 2 years ago
5 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
4/10/2023 - a year ago
6 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
4/10/2023 - a year ago
7 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
4/11/2023 - a year ago
8 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
6/8/2023 - a year ago
9 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
6/8/2023 - a year ago
10 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
6/8/2023 - a year ago
11 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
9/8/2023 - a year ago
12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
9/8/2023 - a year ago
13 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
9/8/2023 - a year ago
14 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
11/28/2023 - a year ago
15 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
12/13/2023 - a year ago
16 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
1/2/2024 - a year ago
17 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
2/27/2024 - 10 months ago
19 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Type: NOAM
-
9/30/2024 - 3 months ago
20 - ABANDONMENT - NO USE STATEMENT FILED
Type: ABN6
-
9/30/2024 - 3 months ago
21 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Type: MAB6
-
1/2/2024 - a year ago
18 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
